Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis

被引：0
|
作者：
Machaon M Bonafede
Anupama Kalsekar
Manjiri Pawaskar
Kimberly M Ruiz
Amelito M Torres
Karen R Kelly
Suellen M Curkendall
机构：
[1] Thomson Reuters Inc,Outcomes Research
[2] Bristol Myers Squibb,Global Health Economics and Outcomes Research
[3] Eli Lilly and Company,Global Health Outcomes: Endocrine/Obesity/Metabolism
[4] Lilly Technology Center,Outcomes Research
[5] Thomson Reuters Inc,Healthcare Research and Analytics
[6] GE Healthcare,Diabetes and Devices Platform
[7] Eli Lilly and Company,undefined
[8] Lilly Technology Center,undefined
来源：
BMC Endocrine Disorders | / 11卷
关键词：
Insulin Therapy; Human Insulin; Basal Insulin; Index Insulin; Mealtime Insulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Insulin deglucec, a new generation ultra-long acting insulin, in a mealtime plus basal regimen in people with type 1 diabetes: comparison to insulin glargine
    Meneghini, L.
    Home, E.
    DeVries, J. H.
    Jendle, J.
    Endahl, L.
    Lyby, K.
    Johansen, T.
    Roberts, A.
    Ratner, R.
    Wendisch, U.
    Birkeland, K. I.
    DIABETOLOGIA, 2010, 53
  • [22] Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    Raskin, P
    Riis, A
    Guthrie, RA
    Jovanovic, L
    Leiter, L
    DIABETES CARE, 2000, 23 (05) : 583 - 588
  • [23] A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients
    Pala, L.
    Mannucci, E.
    Dicembrini, I.
    Rotella, C. M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 (01) : 132 - 135
  • [24] Gradual intensification of premixed insulin lispro therapy vs basal ± mealtime insulin in patients with type 2 diabetes eating light breakfasts
    Giugliano, D.
    Woo, V.
    Shah, S.
    Tracz, M.
    Mistodie, C.
    Calle-Pascual, A.
    Duarte, R.
    Sari, R.
    Deinhard, J.
    Jiletcovici, A. O.
    Wille, S.
    Kiljanski, J.
    DIABETOLOGIA, 2012, 55 : S386 - S386
  • [25] Efficacy and Safety of a Basal-Bolus Regimen of Basal Insulin Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 5 Clinical Trials
    Dailey, George
    Lin, Jay
    Wang, Edward
    DIABETES, 2012, 61 : A284 - A284
  • [26] Beginning a Basal plus Mealtime Insulin Regimen Using Prandial Insulin Aspart in Insulin-Naive Adults With Type 2 Diabetes: Results from the A1chieve Study
    Haddad, Jihad
    Litwak, Leon E.
    Malek, Rachid
    Zilov, Alexey V.
    Chakkarwar, Praful N.
    Khamseh, Mohammad E.
    DIABETES, 2012, 61 : A302 - A302
  • [27] A QUALITATIVE STUDY OF BASAL INSULIN USE BEHAVIORS IN PATIENTS WITH TYPE 2 DIABETES
    Kern, D. M.
    Stephenson, J. J.
    Freeman, E. C.
    Raval, A.
    Bae, J.
    VALUE IN HEALTH, 2017, 20 (05) : A173 - A173
  • [28] Basal insulin requirement in insulin treated patients with type 2 diabetes mellitus
    Wiesli, P
    Lehmann, R
    Kraydenbühl, PA
    Schmid, C
    Spinas, GA
    DIABETES, 2005, 54 : A102 - A102
  • [29] ADDING INSULIN GLARGINE TO ORAL THERAPY IN PATIENTS WITH TYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN
    Pfohl, M.
    Dippel, F. W.
    Kostev, K.
    Kotowa, W.
    VALUE IN HEALTH, 2008, 11 (06) : A509 - A510
  • [30] Pramlintide improved glycemic control and reduced body weight in patients with type 2 diabetes treated with basal insulin (without mealtime insulin) and a thiazolidinedione
    Lorenzi, Gayle
    Frias, Juan
    Lutz, Karen
    Kesty, Nicole
    Zhang, Bei
    Kolterman, Orville
    DIABETES, 2007, 56 : A147 - A147
12345